Holen Sie sich die Stockscreener-App
7.18
3.88%
-0.29
Vorhandelsmarkt:
7.31
0.13
+1.81%
Schlusskurs vom Vortag:
$7.47
Offen:
$7.53
24-Stunden-Volumen:
3.19M
Relative Volume:
0.77
Marktkapitalisierung:
$1.38B
Einnahmen:
$71.80M
Nettoeinkommen (Verlust:
$-183.59M
KGV:
-6.8102
EPS:
-1.0543
Netto-Cashflow:
$-186.52M
1W Leistung:
-4.52%
1M Leistung:
-1.37%
6M Leistung:
-10.70%
1J Leistung:
-7.12%
1-Tages-Spanne:
$7.025
$7.615
1-Wochen-Bereich:
$6.92
$7.615
52-Wochen-Spanne:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
7.18 | 1.38B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com
Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street Zen - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wave Life Sciences (NASDAQ: WVE) proposes one‑for‑one redomiciliation to Delaware - Stock Titan
Wave Life Sciences 2025 Executive Compensation, Governance, and Business Highlights – 10-K/A Report - Minichart
MSN Money - MSN
Canaccord lowers Wave Life Sciences stock price target on valuation By Investing.com - Investing.com India
WVE Maintained by Canaccord Genuity -- Price Target Lowered to $43.00 - GuruFocus
Wave Life Sciences Signals Momentum In Earnings Call - The Globe and Mail
Wave Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay - Stock Titan
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2026 Earnings Call Transcript - Insider Monkey
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $31 - Moomoo
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43 - Moomoo
Canaccord lowers Wave Life Sciences stock price target on valuation - Investing.com
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)? - simplywall.st
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com
RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6%Here's What Happened - MarketBeat
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
WVE Maintained by Truist Securities -- Price Target Lowered to $15 - GuruFocus
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $36 - Moomoo
Truist Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $15 - Moomoo
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Wave Life Sciences: Q1 Earnings Snapshot - theheraldreview.com
Truist assumes coverage on Wave Life Sciences stock with buy rating - Investing.com India
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Advancements - GuruFocus
WAVE Life Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns - simplywall.st
Clear Street Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress By Investing.com - Investing.com South Africa
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress - Investing.com Canada
WAVE Life Sciences Q1 Earnings Call Highlights - MarketBeat
Wave (WVE) Q1 2025 Earnings Call Transcript - The Motley Fool
WAVE Life Sciences (NASDAQ:WVE) Trading 5.5% HigherTime to Buy? - MarketBeat
BofA cuts Wave Life Sciences stock price target on trial focus - Investing.com
Is WAVE Life Sciences (WVE) Overvalued After Q1 2026 8-K? GF Sco - GuruFocus
BofA cuts Wave Life Sciences stock price target on trial focus By Investing.com - Investing.com India
Clear Street cuts Wave Life Sciences stock price target on obesity trial outlook - Investing.com Canada
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast - Investing.com
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Wave Life Sciences (WVE) Reports Strong Q1 Revenue and Advances WVE-007 Development - GuruFocus
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Wave Life Sciences 1Q Research and Development Expenses $47.4M >WVE - Moomoo
Q1 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):